• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Tactile Medical Announces New Appointments to Board of Directors

    1/5/22 4:05:00 PM ET
    $JNJ
    $ORCL
    $PHG
    $TCMD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Computer Software: Prepackaged Software
    Technology
    Get the next $JNJ alert in real time by email

    MINNEAPOLIS, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical") (NASDAQ:TCMD), a medical technology company focused on developing medical devices for the treatment of patients with underserved chronic diseases at home, today announced the appointment of Valerie L. Asbury and D. Brent Shafer to the Company's Board of Directors ("Board"), effective January 5, 2022. Ms. Asbury will serve as a member of both the Audit Committee and the Compliance & Reimbursement Committee. Mr. Shafer will serve as a member of the Audit Committee, the Compensation & Organization Committee, and the Nominating & Corporate Governance Committee. Three long-standing directors will be retiring from the Board ahead of the May shareholder meeting: Peter Soderberg, Richard Nigon and Kevin Roche.

    "We are extremely pleased to welcome Valerie and Brent to our Board; both experienced leaders, adding depth of expertise in the treatment of chronically ill patients and channels to access and support them," said Bill Burke, Chairman of the Board of Tactile Medical. "I would also like to extend my sincere gratitude to Peter, Dick and Kevin for their dedicated years of service. Their counsel and oversight played an important role in helping Tactile Medical become a successful company, eclipsing $200 million in annual revenue."

    Since 2018, Valerie Asbury has served as the President and CEO of LifeScan, a global leader in blood glucose monitoring, serving more than 20 million people with diabetes. Ms. Asbury previously held a series of leadership roles within Johnson & Johnson (NYSE:JNJ) for over 20 years from 1998 to 2018, including executive sales and general management positions. Her most recent position at Johnson & Johnson was Global President of Diabetes Solutions from 2013 to 2018, including the Global LifeScan subsidiary until its sale in October 2018 to Platinum Equity, a leading private investment firm. She holds a Bachelor of Science in Nursing from Vanderbilt University.

    Brent Shafer most recently served as Chairman and CEO of Cerner Corporation from 2018 until September 2021, a global healthcare technology company that was acquired by Oracle Corporation (NYSE:ORCL) in December 2021. Prior to Cerner, Mr. Shafer was Chief Executive Officer of Philips North America, a health technology company and the North American division of Koninklijke Philips N.V. (("Philips", NYSE:PHG, AEX: PHIA)), from 2014 to 2018. Mr. Shafer also served as Chief Executive Officer of the global Philips' Home Healthcare Solutions business from 2010 until 2014. Mr. Shafer previously held a series of leadership roles at Philips, Hill Rom and GE Healthcare. He holds a Bachelor of Science from the University of Utah.

    About Tactile Medical

    Tactile Medical is a leader in developing and marketing at-home therapies for people suffering from underserved, chronic conditions including lymphedema, lipedema, chronic venous insufficiency and chronic pulmonary disease by helping them live better and care for themselves at home. The company collaborates with clinicians to expand clinical evidence, raise awareness, increase access to care, reduce overall healthcare costs and improve the quality of life for tens of thousands of patients each year.  



    Investor Inquiries:
    Mike Piccinino, CFA
    Managing Director
    ICR Westwicke
    [email protected]

    Primary Logo

    Get the next $JNJ alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $JNJ
    $ORCL
    $PHG
    $TCMD

    CompanyDatePrice TargetRatingAnalyst
    Johnson & Johnson
    $JNJ
    7/23/2025Hold → Buy
    Erste Group
    Oracle Corporation
    $ORCL
    7/17/2025$300.00Sector Outperform
    Scotiabank
    Oracle Corporation
    $ORCL
    7/10/2025$270.00Neutral → Overweight
    Piper Sandler
    Oracle Corporation
    $ORCL
    7/2/2025$235.00 → $245.00Outperform
    BMO Capital Markets
    Oracle Corporation
    $ORCL
    6/30/2025$250.00Hold → Buy
    Stifel
    Oracle Corporation
    $ORCL
    6/18/2025$220.00 → $250.00Buy
    Guggenheim
    Oracle Corporation
    $ORCL
    6/13/2025$235.00Market Perform → Outperform
    BMO Capital Markets
    Oracle Corporation
    $ORCL
    6/9/2025$175.00 → $200.00Market Perform
    BMO Capital Markets
    More analyst ratings

    $JNJ
    $ORCL
    $PHG
    $TCMD
    SEC Filings

    See more
    • SEC Form 6-K filed by Koninklijke Philips N.V. NY Registry Shares

      6-K - KONINKLIJKE PHILIPS NV (0000313216) (Filer)

      7/29/25 7:47:58 AM ET
      $PHG
      Medical Electronics
      Health Care
    • SEC Form 10-Q filed by Johnson & Johnson

      10-Q - JOHNSON & JOHNSON (0000200406) (Filer)

      7/24/25 4:04:24 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 13F-HR filed by Johnson & Johnson

      13F-HR - JOHNSON & JOHNSON (0000200406) (Filer)

      7/22/25 12:33:19 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JNJ
    $ORCL
    $PHG
    $TCMD
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • July 21, 2023 - FDA Roundup: July 21, 2023

      For Immediate Release: July 21, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA Center for Tobacco Products (CTP) announced that the center will host a virtual listening session on Aug. 22, 2023. During this listening session, CTP is requesting feedback on the development of a new 5-year strategic plan for the center, includin

      7/21/23 4:02:23 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • May 5, 2022 - Coronavirus (COVID-19) Update: FDA Limits Use of Janssen COVID-19 Vaccine to Certain Individuals

      For Immediate Release: May 05, 2022 Today, the U.S. Food and Drug Administration has limited the authorized use of the Janssen COVID-19 Vaccine to individuals 18 years of age and older for whom other authorized or approved COVID-19 vaccines are not accessible or clinically appropriate, and to individuals 18 years of age and older who elect to receive the Janssen COVID-19 Vaccine because they would otherwise not

      5/5/22 4:51:11 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • August 18, 2021 - Joint Statement from HHS Public Health and Medical Experts on COVID-19 Booster Shots

      For Immediate Release: August 18, 2021 Today, public health and medical experts from the U.S. Department of Health and Human Services (HHS) released the following statement on the Administration’s plan for COVID-19 booster shots for the American people. The statement is attributable to Dr. Rochelle Walensky, Director of the Centers for Disease Control and Prevention (CDC); Dr. Janet Woodcock, Acting Commissione

      8/18/21 1:06:11 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JNJ
    $ORCL
    $PHG
    $TCMD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Johnson & Johnson Launches VIRTUGUIDE™ AI-Powered Patient-Matched Lapidus System in U.S. to Reduce Complexity in Bunion Surgery for Millions

      Early VIRTUGUIDE™ surgeons report a 30-minute reduction in surgical time versus traditional treatment1,2,*,** WEST CHESTER, Penn., July 29, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) – Johnson & Johnson MedTech, a global leader in orthopaedic technologies and solutions, today announced the launch of the VIRTUGUIDE™ System. This AI-powered, patient-matched solution is designed to support Lapidus procedures2, a type of bunion surgery that helps realign the foot by joining two bones near the arch (the first metatarsal bone and the medial cuneiform).3 The system uses pre-operative planning software, developed in collaboration with PeekMed®, to assess each patient's bunion and make persona

      7/29/25 8:03:00 AM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PNC Bank Announces Integration with Oracle Fusion Cloud ERP for Embedded Banking

      Connection Enables PNC PINACLE Connect® Clients to Seamlessly Access Treasury Services Within Market-leading Cloud ERP PITTSBURGH, July 29, 2025 /PRNewswire/ -- PNC Bank today announced the integration of its award-winning embedded banking platform, PINACLE Connect®, with Oracle Fusion Cloud Enterprise Resource Planning (ERP). PNC corporate and commercial banking clients now have seamless connectivity to key banking services directly within Oracle Cloud ERP, helping streamline financial operations and enhance overall efficiency. The new embedded banking experience, which uses

      7/29/25 8:01:00 AM ET
      $ORCL
      $PNC
      Computer Software: Prepackaged Software
      Technology
      Major Banks
      Finance
    • Johnson & Johnson files with U.S. FDA to include new evidence in TREMFYA® (guselkumab) label as the only IL-23 inhibitor to demonstrate significant inhibition of joint structural damage in active psoriatic arthritis

      Submission is supported by 24-week results from the Phase 3b APEX study in adults with active psoriatic arthritis treated with TREMFYA®, the only dual-acting IL-23 inhibitor     HORSHAM, Pa., July 29, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval to include new evidence in the TREMFYA® (guselkumab) label for the inhibition of progression of structural damage in adults with active psoriatic arthritis (PsA). The submission is s

      7/29/25 8:00:00 AM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JNJ
    $ORCL
    $PHG
    $TCMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by EVP, Chief Legal Officer Levey Stuart

      4 - ORACLE CORP (0001341439) (Issuer)

      7/28/25 4:08:17 PM ET
      $ORCL
      Computer Software: Prepackaged Software
      Technology
    • Director Seligman Naomi O sold $770,656 worth of shares (3,303 units at $233.32), decreasing direct ownership by 10% to 31,447 units (SEC Form 4)

      4 - ORACLE CORP (0001341439) (Issuer)

      7/18/25 4:26:23 PM ET
      $ORCL
      Computer Software: Prepackaged Software
      Technology
    • EVP, Innovative Medicine, R&D Reed John C sold $3,129,830 worth of shares (19,137 units at $163.55), decreasing direct ownership by 64% to 10,658 units (SEC Form 4)

      4 - JOHNSON & JOHNSON (0000200406) (Issuer)

      7/18/25 4:12:41 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JNJ
    $ORCL
    $PHG
    $TCMD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Fairhead Rona Alison bought $112,258 worth of shares (480 units at $233.87), increasing direct ownership by 2% to 22,110 units (SEC Form 4)

      4 - ORACLE CORP (0001341439) (Issuer)

      7/9/25 4:39:51 PM ET
      $ORCL
      Computer Software: Prepackaged Software
      Technology
    • Director Boskin Michael J bought $111,145 worth of shares (1,682 units at $66.08), increasing direct ownership by 2% to 92,458 units (SEC Form 4)

      4 - ORACLE CORP (0001341439) (Issuer)

      3/21/25 8:43:30 PM ET
      $ORCL
      Computer Software: Prepackaged Software
      Technology
    • Director Moorman Charles W bought $947,913 worth of shares (5,500 units at $172.35) (SEC Form 4)

      4 - ORACLE CORP (0001341439) (Issuer)

      2/14/25 4:41:16 PM ET
      $ORCL
      Computer Software: Prepackaged Software
      Technology

    $JNJ
    $ORCL
    $PHG
    $TCMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Johnson & Johnson upgraded by Erste Group

      Erste Group upgraded Johnson & Johnson from Hold to Buy

      7/23/25 8:55:43 AM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Scotiabank initiated coverage on Oracle with a new price target

      Scotiabank initiated coverage of Oracle with a rating of Sector Outperform and set a new price target of $300.00

      7/17/25 8:08:11 AM ET
      $ORCL
      Computer Software: Prepackaged Software
      Technology
    • Oracle upgraded by Piper Sandler with a new price target

      Piper Sandler upgraded Oracle from Neutral to Overweight and set a new price target of $270.00

      7/10/25 8:27:04 AM ET
      $ORCL
      Computer Software: Prepackaged Software
      Technology

    $JNJ
    $ORCL
    $PHG
    $TCMD
    Leadership Updates

    Live Leadership Updates

    See more
    • New AI Rollouts Signal Shift From Hype to Healthcare Reality

      USA News Group News CommentaryIssued on behalf of Avant Technologies Inc. VANCOUVER, BC, June 24, 2025 /PRNewswire/ -- With populations again, and chronic diseases on the rise, global healthcare systems are facing enormous challenges ahead. However, there is hope on the horizon to alleviate some of these burdens, coming from the rise of AI in healthcare, as the new tech is proving it can improve diagnostic accuracies, drug discoveries, and administration work flow. Healthcare leaders are already reporting benefits, including reduced clinician workloads through voice-based AI tools and the use of AI agents to boost efficiency and support smarter care delivery. Behind the scenes, the tech is b

      6/24/25 9:45:00 AM ET
      $LLY
      $PHG
      $PLTR
      $WAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical Electronics
      Computer Software: Prepackaged Software
    • Johnson & Johnson Elects Daniel Pinto, President, JPMorganChase to its Board of Directors

      Johnson & Johnson (NYSE:JNJ) announced today that Daniel Pinto, President, JPMorganChase, has been elected to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250610707025/en/ "We are thrilled to have Daniel join Johnson & Johnson's Board of Directors," said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. "He is an exceptional leader with deep financial expertise and understanding of global capital markets. Daniel's unique perspective and wealth of experience will be a tremendous asset to Johnson & Johnson as we continue to invest in and advance the next generation of healthcare inno

      6/10/25 4:51:00 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Philips shareholders approve all proposals at the AGM 2025

      May 8, 2025 Amsterdam, the Netherlands – Royal Philips (NYSE:PHG, AEX: PHIA)), today announced that its shareholders approved all proposals at the Annual General Meeting of Shareholders (AGM) 2025, including: The re-appointment of Ms Indra Nooyi and Ms Chua Sock Koong as members of the Supervisory Board.The appointment of Mr Bob White as a new member of the Supervisory Board.The re-appointment of Mr Marnix van Ginneken as member of the Board of Management. The discharge of the members of the Board of Management, and of the members of the Supervisory Board.A full overview of the resolutions taken at the AGM 2025 can be found below. Feike Sijbesma, Chairman of Philips' Supervisory Board, sa

      5/8/25 12:16:51 PM ET
      $PHG
      Medical Electronics
      Health Care

    $JNJ
    $ORCL
    $PHG
    $TCMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Tactile Systems Technology Inc.

      SC 13G/A - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Subject)

      11/13/24 7:29:11 PM ET
      $TCMD
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Tactile Systems Technology Inc.

      SC 13G - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Subject)

      11/13/24 5:04:27 PM ET
      $TCMD
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Tactile Systems Technology Inc.

      SC 13G - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Subject)

      11/8/24 3:21:42 PM ET
      $TCMD
      Medical/Dental Instruments
      Health Care

    $JNJ
    $ORCL
    $PHG
    $TCMD
    Financials

    Live finance-specific insights

    See more
    • Philips builds strong order intake momentum and drives margin expansion in Q2

      July 29, 2025 Q2 2025 Group Highlights Comparable order intake growth 6%Group sales EUR 4.3 billion, reflecting 1% increase in comparable salesIncome from operations EUR 400 millionAdjusted EBITA margin increased 130 bps to 12.4% of salesFree cash flow increased to EUR 230 millionPhilips increases full year 2025 outlook for Adjusted EBITA margin and free cash flow; reiterates comparable sales growth outlook Roy Jakobs, CEO of Royal Philips:"We are focused on driving profitable growth and delivering better care for more people. We built order intake growth momentum, supported by our recently launched AI-powered innovations. Our multi-year agreement with the Indonesian Ministry of Health re

      7/29/25 1:00:00 AM ET
      $PHG
      Medical Electronics
      Health Care
    • Tactile Medical to Release Second Quarter of Fiscal Year 2025 Financial Results on August 4, 2025

      MINNEAPOLIS, July 21, 2025 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that second quarter of fiscal year 2025 financial results will be released after the market closes on Monday, August 4, 2025. Management will host a conference call with a question and answer session at 5:00 p.m. Eastern Time on August 4, 2025, to discuss the results of the quarter. Those who would like to participate may dial 877-407-3088 (201-389-0927 for international callers) and provide access code 13754589. A live webcast of the call will also be provided o

      7/21/25 4:05:00 PM ET
      $TCMD
      Medical/Dental Instruments
      Health Care
    • Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2025

      Johnson & Johnson (NYSE:JNJ) today announced that its Board of Directors has declared a cash dividend for the third quarter of 2025 of $1.30 per share on the company's common stock. The dividend is payable on September 9, 2025 to shareholders of record at the close of business on August 26, 2025. The ex-dividend date is August 26, 2025. About Johnson & Johnson At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely po

      7/16/25 6:25:00 AM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care